These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415 [TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40. Jhaveri CD; Liu D; Maguire MG; Glassman AR; Grigorian RA; Jampol LM; Kingsley RM; MacCumber MW; Martin DF; Maturi RK; Velez G; Sun JK; Ophthalmology; 2024 Aug; 131(8):967-974. PubMed ID: 38336282 [TBL] [Abstract][Full Text] [Related]
11. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007419. PubMed ID: 30325017 [TBL] [Abstract][Full Text] [Related]
12. Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry. Bhandari S; Nguyen V; Fraser-Bell S; Mehta H; Viola F; Baudin F; Gabrielle PH; Creuzot-Garcher C; Gillies M; Barthelmes D Ophthalmology; 2020 May; 127(5):608-615. PubMed ID: 31932092 [TBL] [Abstract][Full Text] [Related]
13. Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T. Bressler NM; Beaulieu WT; Maguire MG; Glassman AR; Blinder KJ; Bressler SB; Gonzalez VH; Jampol LM; Melia M; Sun JK; Wells JA; Am J Ophthalmol; 2018 Nov; 195():93-100. PubMed ID: 30077569 [TBL] [Abstract][Full Text] [Related]
14. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK; JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA; JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939 [TBL] [Abstract][Full Text] [Related]
17. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network. Krick TW; Bressler NM Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861 [TBL] [Abstract][Full Text] [Related]
18. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. Cai S; Bressler NM Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425 [TBL] [Abstract][Full Text] [Related]
19. Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti-Vascular Endothelial Growth Factor Therapy: A Post Hoc Analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) Trial. Gurudas S; Patrao N; Nicholson L; Sen P; Ramu J; Sivaprasad S; Hykin P JAMA Ophthalmol; 2022 Feb; 140(2):143-150. PubMed ID: 34989804 [TBL] [Abstract][Full Text] [Related]
20. A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema. Wiley HE; Thompson DJ; Bailey C; Chew EY; Cukras CA; Jaffe GJ; Lee RW; Loken EK; Meyerle CB; Wong W; Ferris FL Ophthalmology; 2016 Apr; 123(4):841-9. PubMed ID: 26875003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]